With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. | With dosing underway in a pivotal phase 3 trial, Star ...

The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring ...

Pharma and biotech companies have access to an unprecedented variety of health data, from electronic health records and ...

While the prevalence of Parkinson’s disease (PD) has doubled over the past 20 years, the treatment paradigm has remained ...

The industry’s mRNA alliance is demanding steady FDA leadership, warning that the current “unprecedented turmoil” at the ...

Freenome is taking itself public via a special purpose acquisition company, also known as a SPAC deal, to help raise funds in ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

All this data builds Jefferies’ argument: the FDA change could help boost return on investment and therefore drive R&D spend.

Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire Foresight ...

“SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they ...

The outside advisors analyzed the results of the RELIEVE-HF pivotal trial, which randomized 508 patients to either receive ...

The FDA has named Tracy Beth Høeg, M.D., Ph.D., as acting director of its Center for Drug Evaluation and Research, continuing ...